Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Operating Expenses (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Operating Expenses for 15 consecutive years, with $12.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 3.9% year-over-year to $12.7 million, compared with a TTM value of $43.5 million through Sep 2025, down 9.92%, and an annual FY2024 reading of $45.0 million, up 32.18% over the prior year.
  • Operating Expenses was $12.7 million for Q3 2025 at Fennec Pharmaceuticals, up from $12.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $17.6 million in Q4 2022 and bottomed at -$5.0 million in Q2 2022.
  • Average Operating Expenses over 5 years is $8.2 million, with a median of $8.4 million recorded in 2023.
  • The sharpest move saw Operating Expenses plummeted 726.12% in 2022, then surged 259.53% in 2023.
  • Year by year, Operating Expenses stood at $4.2 million in 2021, then skyrocketed by 321.81% to $17.6 million in 2022, then tumbled by 31.1% to $12.1 million in 2023, then dropped by 26.95% to $8.9 million in 2024, then skyrocketed by 42.8% to $12.7 million in 2025.
  • Business Quant data shows Operating Expenses for FENC at $12.7 million in Q3 2025, $12.4 million in Q2 2025, and $9.6 million in Q1 2025.